Cost-effectiveness of an intervention to reduce HIV/STI incidence and promote condom use among female sex workers in the Mexico-US border region

José L Burgos, Julia A Gaebler, Steffanie A Strathdee, Remedios Lozada, Hugo Staines, Thomas L Patterson, José L Burgos, Julia A Gaebler, Steffanie A Strathdee, Remedios Lozada, Hugo Staines, Thomas L Patterson

Abstract

Background: Previous research demonstrated efficacy of a brief behavioral intervention to reduce incidence of HIV and sexually transmitted infections (STIs) among female sex workers (FSWs) in Tijuana and Ciudad Juarez, Mexico, cities on Mexico's border with the US. We assessed this intervention's cost-effectiveness.

Methodology and principal findings: A life-time Markov model was developed to estimate HIV cases prevented, changes in quality-adjusted life expectancy (QALE), and costs per additional quality-adjusted life year gained (QALY), comparing (in US$2,009) no intervention to a once-only and annual intervention. Future costs and health benefits were discounted annually at 3%. Sensitivity analyses evaluated model robustness. We found that for a hypothetical 1,000 FSWs receiving the once-only intervention, there were 33 HIV cases prevented and 5.7 months of QALE gained compared to no intervention. The additional cost per QALY gained was US$183. For FSWs receiving the intervention annually, there were 29 additional HIV cases prevented and 4.5 additional months of QALE compared to the once-only intervention. The additional cost per QALY was US$1,075. When highly active antiretroviral therapy (HAART) was included in the model, the annual intervention strategy resulted in net savings and dominated both once-only and no intervention strategies, and remained robust across extensive sensitivity analyses. Even when considering clinical benefits from HAART, ignoring added costs, the cost per QALY gained remained below three times the Mexican GDP per capita, and below established cost-effectiveness thresholds.

Conclusions/significance: This brief intervention was shown to be cost-effective among FSWs in two Mexico-US border cities and may have application for FSWs in other resource-limited settings.

Trial registration: ClinicalTrials.gov NCT00338845.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. CONSORT flow chart.
Figure 1. CONSORT flow chart.
* All participants who completed follow-up were analyzed for STI incidence. Some participants were lacking follow-up sexual risk data. See Table 2, p. 2054, in Patterson et al. (2008), Am J Public Health 98: 2051–2057 for details.
Figure 2. Schematic representation of the Markov…
Figure 2. Schematic representation of the Markov model used for the cost effectiveness analysis for the Mujer Segura intervention.
a = Female sex workers; b = No HIV or sexually transmitted infections; c = Gonorrhea or Chlamydia trachomatis infection; d = Syphilis infection; e = HIV infection (no other sexually transmitted infections); f = HIV and gonorrhea or Chlamydia co-infection; g = HIV and syphilis co-infection.
Figure 3. Tornado Diagram showing results of…
Figure 3. Tornado Diagram showing results of one way sensitivity analyses comparing no intervention to the Mujer Segura intervention offered once only.
The vertical dotted line represents the base-case analysis incremental cost per QALY (quality-adjusted life years) gained. The numbers at the end of each bar represents the range over which each of the variables was changed. a = Changes in annual discount rate used for costs and health benefits; b = Incidence is presented per 100 person-years; c = quality adjusted life years.
Figure 4. Tornado Diagram showing results of…
Figure 4. Tornado Diagram showing results of one way sensitivity analyses comparing the Mujer Segura intervention offered once only and annually.
The vertical dotted line represents the base-case analysis incremental cost per QALY (quality-adjusted life years) gained. The numbers at the end of each bar represents the range over which each of the variables was changed. a = Changes in annual discount rate used for costs and health benefits; b = Incidence is presented per 100 person-years; c = quality adjusted life years.
Figure 5. Cost-effectiveness acceptability curve for the…
Figure 5. Cost-effectiveness acceptability curve for the Mujer Segura intervention offered once or annually.
Results of the probabilistic sensitivity analysis, represented as a cost-effectiveness acceptability curve. The cost per QALY (quality adjusted life years) gained from the Mujer Segura intervention is plotted on the x-axis, and the probability that the intervention is cost-effective across these values is plotted on the y-axis. The Mujer Segura intervention offered once or annually resulted in a cost-effectiveness below a willingness to pay treshold of three times the GDP in Mexico per QALY gained (equivalent to US$29,300). a = Mujer Segura behavioral intervention; b = Quality adjusted life year.

References

    1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.
    1. UNAIDS. Mexico Fact Sheet on HIV and AIDS. 2008. Available: . Accessed 28 August 2009.
    1. Bautista-Arredondo S, Dmytraczenko T, Kombe G, Bertozzi SM. Costing of scaling up HIV/AIDS treatment in Mexico. Salud Pública Mex. 2008;50(Suppl 4):S437–444.
    1. Valdespino-Gómez JL, García-García ML, del Río-Zolezzi A, Loo-Méndez E, Magis-Rodríguez C, et al. Epidemiología del SIDA/VIH en México; de 1983 a marzo de 1995. [The epidemiology of AIDS/HIV in Mexico: from 1983 to March 1995]. Salud Pública Mex. 1995;37:520–524.
    1. del Rio-Zolezzi A, Liguori AL, Magis-Rodrí­guez C, Valdespino-Gómez JL, Garcia-Garcia M, et al. [The HIV/AIDS epidemic and women in Mexico]. Salud Pública Mex. 1995;37:581–591.
    1. UNAIDS. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. Epidemiological Fact Sheet on HIV and AIDS 2008. Geneva: UNAIDS; 2008.
    1. Uribe-Salas F, Hernandez-Avila M, Conde-Gonzalez CJ, Juarez-Figueroa L, Allen B, et al. Low prevalences of HIV infection and sexually transmitted disease among female commercial sex workers in Mexico City. Am J Public Health. 1997;87:1012–1015.
    1. Patterson TL, Semple SJ, Staines H, Lozada R, Orozovich P, et al. Prevalence and correlates of HIV infection among female sex workers in 2 Mexico-US border cities. J Infect Dis. 2008;197:728–732.
    1. Rekart ML. Sex-work harm reduction. Lancet. 2005;366:2123–2134.
    1. Bertozzi SM, Laga M, Bautista-Arredondo S, Coutinho A. Making HIV prevention programmes work. Lancet. 2008;372:831–844.
    1. Patterson TL, Semple SJ, Fraga M, Bucardo J, Davila-Fraga W, et al. An HIV prevention intervention for sex workers in Tijuana, Mexico: A pilot study. Hisp J Behav Sci. 2005;27:82–100.
    1. Cohen DA, Wu SY, Farley TA. Comparing the cost-effectiveness of HIV prevention interventions. J Acquir Immune Defic Syndr. 2004;37:1404–1414.
    1. Patterson TL, Mausbach B, Lozada R, Staines-Orozco H, Semple SJ, et al. Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico. Am J Public Health. 2008;98:2051–2057.
    1. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
    1. Gold MR. Standardizing cost-effectiveness analyses: the panel on cost-effectiveness in health and medicine. Acad Radiol. 1998;5(Suppl 2):S351–354.
    1. World Health Organization (WHO) CHOosing Interventions that are Cost Effective (WHO-CHOICE): Threshold values for intervention cost-effectiveness by region (tables listing prices and other relevant information for cost analysis). 2009. Available: . Accessed 24 March 2009.
    1. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946–954.
    1. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009;23:335–342.
    1. Soler Claudin C. [Universal access, six years results in the Mexico City HIV/AIDS Program]. Salud Pública Mex. 2009;51:26–33.
    1. Strathdee SA, Mausbach B, Lozada R, Staines-Orozco H, Semple SJ, et al. Predictors of sexual risk reduction among Mexican female sex workers enrolled in a behavioral intervention study. J Acquir Immune Defic Syndr. 2009;51(Suppl 1):S42–46.
    1. National Alliance of State and Territorial AIDS Directors (NASTAD) HIV/AIDS en la Frontera: U.S.–Mexico Border Epidemiologic Profile. 2009. Available: . Accessed 15 July 2009.
    1. CONAPO. Probabilidades de fallecer por sexo y edad, 2005–2050. Mexico City Consejo Nacional de Poblacion Republica Mexicana. 2009. Available: . Accessed 1 August 2009.
    1. Mausbach BT, Semple SJ, Strathdee SA, Zians J, Patterson TL. Efficacy of a behavioral intervention for increasing safer sex behaviors in HIV-negative, heterosexual methamphetamine users: results from the Fast-Lane Study. Ann Behav Med. 2007;34:263–274.
    1. Mausbach BT, Semple SJ, Strathdee SA, Zians J, Patterson TL. Efficacy of a behavioral intervention for increasing safer sex behaviors in HIV-positive MSM methamphetamine users: results from the EDGE study. Drug Alcohol Depend. 2007;87:249–257.
    1. CENSIDA. Precios antiretrovirales: Precios actualizados. 2008. Available: . Accessed 27 April 2009.
    1. Patterson TL, Mausbach B, Lozada R, Staines-Orozco H, Semple SJ, et al. Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico. American Journal of Public Health. 2008;98:2051–2057.
    1. Muennig P. Cost-effectiveness analyses in health: a practical approach. San Francisco: Jossey-Bass; 2008. p. xvi, 266.
    1. Centers for Disease Control and Prevention (CDC) HIV/AIDS Surveillance Report, 2005. Vol. 17, rev. ed. Atlanta: U.S. Department of Health and Human Services; 2007. pp. 1–46.
    1. Belanger F, Meyer L, Carre N, Coutellier A, Deveau C. Influence of age at infection on human immunodeficiency virus disease progression to different clinical endpoints: the SEROCO cohort (1988–1994). The Seroco Study Group. Int J Epidemiol. 1997;26:1340–1345.
    1. Strathdee SA, Magis-Rodriguez C. Mexico's evolving HIV epidemic. JAMA. 2008;300:571–573.
    1. Bautista-Arredondo S, Gadsden P, Harris JE, Bertozzi SM. Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework. AIDS. 2008;22(Suppl 1):S67–74.
    1. Sweat M, Kerrigan D, Moreno L, Rosario S, Gomez B, et al. Cost-effectiveness of environmental-structural communication interventions for HIV prevention in the female sex industry in the Dominican Republic. J Health Commun. 2006;11(Suppl 2):123–142.
    1. Holtgrave D. Evidence-based efforts to prevent HIV infection: an overview of current status and future challenges. Clin Infect Dis. 2007;45(Suppl 4):S293–299.
    1. Marseille E, Dandona L, Marshall N, Gaist P, Bautista-Arredondo S, et al. HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res. 2007;7:108.
    1. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21:685–692.

Source: PubMed

3
Abonnere